FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038654865> ?p ?o ?g. }

• W2038654865 endingPage "151" @default.
• W2038654865 startingPage "147" @default.
• W2038654865 abstract "Purpose Acyclovir and high doses of intramuscular leukocyte interferon have been shown to prevent dissemination of herpes zoster in cancer patients with localized herpes zoster. With the availability of recombinant interferon, we decided to conduct a multicenter, placebo-controlled, double-blind trial of intramuscular recombinant interferon alpha-2a to assess its efficacy and safety in the treatment of localized herpes zoster in immunosuppressed patients with cancer. Patients and methods Immunosuppressed cancer patients with localized herpes zoster were randomly assigned to receive placebo, 36 × 106 units of recombinant interferon alpha-2a per day, or 68 × 106 units of recombinant interferon alpha-2a per day. Due to frequent adverse effects, the 68 × 106 unit dose of interferon was discontinued prior to conclusion of the trial. Results Dissemination of herpes zoster occurred in 14 of the 24 patients (58 percent) who received placebo but in only four of 24 recipients (17 percent) of 36 × 106 units of interferon per day (p =0.003). Adverse effects (fever, chills, headaches, gastrointestinal irritability, fatigue, and myalgias) were more common or severe in interferon-treated patients. Conclusion These results suggest that interferon modifies the severity of herpes zoster in immunosuppressed patients with cancer but is associated with frequent side effects. Acyclovir and high doses of intramuscular leukocyte interferon have been shown to prevent dissemination of herpes zoster in cancer patients with localized herpes zoster. With the availability of recombinant interferon, we decided to conduct a multicenter, placebo-controlled, double-blind trial of intramuscular recombinant interferon alpha-2a to assess its efficacy and safety in the treatment of localized herpes zoster in immunosuppressed patients with cancer. Immunosuppressed cancer patients with localized herpes zoster were randomly assigned to receive placebo, 36 × 106 units of recombinant interferon alpha-2a per day, or 68 × 106 units of recombinant interferon alpha-2a per day. Due to frequent adverse effects, the 68 × 106 unit dose of interferon was discontinued prior to conclusion of the trial. Dissemination of herpes zoster occurred in 14 of the 24 patients (58 percent) who received placebo but in only four of 24 recipients (17 percent) of 36 × 106 units of interferon per day (p =0.003). Adverse effects (fever, chills, headaches, gastrointestinal irritability, fatigue, and myalgias) were more common or severe in interferon-treated patients. These results suggest that interferon modifies the severity of herpes zoster in immunosuppressed patients with cancer but is associated with frequent side effects." @default.
• W2038654865 created "2016-06-24" @default.
• W2038654865 creator A5001736304 @default.
• W2038654865 creator A5004106499 @default.
• W2038654865 creator A5017566768 @default.
• W2038654865 creator A5026772130 @default.
• W2038654865 creator A5034866757 @default.
• W2038654865 creator A5036081415 @default.
• W2038654865 creator A5042372640 @default.
• W2038654865 creator A5045351648 @default.
• W2038654865 creator A5048913229 @default.
• W2038654865 creator A5058275680 @default.
• W2038654865 creator A5067587294 @default.
• W2038654865 creator A5073501431 @default.
• W2038654865 creator A5085177083 @default.
• W2038654865 creator A5091611874 @default.
• W2038654865 date "1988-08-01" @default.
• W2038654865 modified "2023-10-13" @default.
• W2038654865 title "Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer" @default.
• W2038654865 cites W2018879260 @default.
• W2038654865 cites W2022548898 @default.
• W2038654865 cites W2042693397 @default.
• W2038654865 cites W2045343664 @default.
• W2038654865 cites W2075889516 @default.
• W2038654865 cites W2091371644 @default.
• W2038654865 cites W2113909835 @default.
• W2038654865 cites W2119213671 @default.
• W2038654865 cites W2128394628 @default.
• W2038654865 cites W2336194566 @default.
• W2038654865 cites W2337397650 @default.
• W2038654865 cites W2338795352 @default.
• W2038654865 cites W588294936 @default.
• W2038654865 doi "https://doi.org/10.1016/s0002-9343(88)80333-4" @default.
• W2038654865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3041829" @default.
• W2038654865 hasPublicationYear "1988" @default.
• W2038654865 type Work @default.
• W2038654865 sameAs 2038654865 @default.
• W2038654865 citedByCount "32" @default.
• W2038654865 countsByYear W20386548652012 @default.
• W2038654865 countsByYear W20386548652013 @default.
• W2038654865 countsByYear W20386548652016 @default.
• W2038654865 countsByYear W20386548652017 @default.
• W2038654865 countsByYear W20386548652018 @default.
• W2038654865 countsByYear W20386548652019 @default.
• W2038654865 countsByYear W20386548652021 @default.
• W2038654865 crossrefType "journal-article" @default.
• W2038654865 hasAuthorship W2038654865A5001736304 @default.
• W2038654865 hasAuthorship W2038654865A5004106499 @default.
• W2038654865 hasAuthorship W2038654865A5017566768 @default.
• W2038654865 hasAuthorship W2038654865A5026772130 @default.
• W2038654865 hasAuthorship W2038654865A5034866757 @default.
• W2038654865 hasAuthorship W2038654865A5036081415 @default.
• W2038654865 hasAuthorship W2038654865A5042372640 @default.
• W2038654865 hasAuthorship W2038654865A5045351648 @default.
• W2038654865 hasAuthorship W2038654865A5048913229 @default.
• W2038654865 hasAuthorship W2038654865A5058275680 @default.
• W2038654865 hasAuthorship W2038654865A5067587294 @default.
• W2038654865 hasAuthorship W2038654865A5073501431 @default.
• W2038654865 hasAuthorship W2038654865A5085177083 @default.
• W2038654865 hasAuthorship W2038654865A5091611874 @default.
• W2038654865 hasConcept C104317684 @default.
• W2038654865 hasConcept C126322002 @default.
• W2038654865 hasConcept C142724271 @default.
• W2038654865 hasConcept C185592680 @default.
• W2038654865 hasConcept C197934379 @default.
• W2038654865 hasConcept C203014093 @default.
• W2038654865 hasConcept C204787440 @default.
• W2038654865 hasConcept C2522874641 @default.
• W2038654865 hasConcept C27081682 @default.
• W2038654865 hasConcept C2776178377 @default.
• W2038654865 hasConcept C2779001537 @default.
• W2038654865 hasConcept C2909179924 @default.
• W2038654865 hasConcept C40767141 @default.
• W2038654865 hasConcept C55493867 @default.
• W2038654865 hasConcept C71924100 @default.
• W2038654865 hasConcept C90924648 @default.
• W2038654865 hasConceptScore W2038654865C104317684 @default.
• W2038654865 hasConceptScore W2038654865C126322002 @default.
• W2038654865 hasConceptScore W2038654865C142724271 @default.
• W2038654865 hasConceptScore W2038654865C185592680 @default.
• W2038654865 hasConceptScore W2038654865C197934379 @default.
• W2038654865 hasConceptScore W2038654865C203014093 @default.
• W2038654865 hasConceptScore W2038654865C204787440 @default.
• W2038654865 hasConceptScore W2038654865C2522874641 @default.
• W2038654865 hasConceptScore W2038654865C27081682 @default.
• W2038654865 hasConceptScore W2038654865C2776178377 @default.
• W2038654865 hasConceptScore W2038654865C2779001537 @default.
• W2038654865 hasConceptScore W2038654865C2909179924 @default.
• W2038654865 hasConceptScore W2038654865C40767141 @default.
• W2038654865 hasConceptScore W2038654865C55493867 @default.
• W2038654865 hasConceptScore W2038654865C71924100 @default.
• W2038654865 hasConceptScore W2038654865C90924648 @default.
• W2038654865 hasIssue "2" @default.
• W2038654865 hasLocation W20386548651 @default.
• W2038654865 hasLocation W20386548652 @default.
• W2038654865 hasOpenAccess W2038654865 @default.
• W2038654865 hasPrimaryLocation W20386548651 @default.
• W2038654865 hasRelatedWork W137427207 @default.

• next